While arch rival Eli Lilly and Company (LLY) spent most of the past two years innovating and catching up with the NVO’s dominance, it still wasn’t sufficient to surpass the Danish biopharma ...

Drugmaker Eli ... expand Lilly's leadership in the weight loss and diabetes treatment categories with another likely blockbuster drug. Second, it should broaden the market for the company's ...

Eli Lilly stock has been a big-time winner ... retaliatory tariffs from other countries could also weigh on Lilly's business; the company could start to see diminished brand equity in ...

Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories. U.S. markets faced heightened volatility this week as the Trump ...

From late 2020 to the summer of 2024, Eli Lilly & Co ... Billions Since 2016, Lilly’s revenue grew by 60% but income grew by 91%. Typically, you would not expect a company growing at its ...

Eli Lilly's new experimental pill called orforglipron, helped patients shed weight and control blood sugar as well as blockbuster drug Ozempic in a trial of diabetes patients, and the company ...

Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced success Thursday of its Phase 3 clinical trial for a once-daily GLP-1 pill — an oral form of the blockbuster medication used for ...

Shares in Chugai Pharmaceutical, the Japanese company that invented the drug and licensed it to Eli Lilly in 2018, soared to a record high on Friday in Tokyo, jumping 16 per cent higher on the ...

Lilly's already holding its own in immunology with Taltz, which made nearly $3.3 billion in sales last year. Omvoh could carve a niche for itself in the Crohn's disease market. Ebglyss should also ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other other firms that ended the week strong. The stock market ended the shortened trading ...

We recently published a list of 10 Firms End Stronger, Buck Muted Broader Market Trading. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other ...